Melanoma: Targeting signaling pathways and RaLP

Luigi Pasini, Margherita Y. Turco, Lucilla Luzi, Ewa Aladowicz, Ernesta Fagiani, Luisa Lanfrancone

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Metastatic melanoma remains one of the most aggressive forms of cancer, with a survival expectation of above six months only in rare cases. Despite advances in the characterization of the underlying molecular pathways and in the development of specific targeted treatments, available chemo- and immuno-therapy are unable to prolong survival significantly in advanced-stage melanoma. Rai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target. Objective: To summarize progress in the ongoing therapeutic approaches to metastatic melanoma and discuss RaLP as a potential novel therapeutic target. Methods: Current understanding of the major signaling pathways involved in melanoma metastatization and of the corresponding pharmacological inhibitors is discussed. Conclusion : RaLP might represent a new drugable target for the treatment of metastatic disease.

Original languageEnglish
Pages (from-to)93-104
Number of pages12
JournalExpert Opinion on Therapeutic Targets
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Melanoma
Proteins
Chemotherapy
src Homology Domains
Therapeutics
Pharmacology
Neoplasms

Keywords

  • Metastatic melanoma
  • RaLP
  • Shc family
  • Targeted inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Melanoma : Targeting signaling pathways and RaLP. / Pasini, Luigi; Turco, Margherita Y.; Luzi, Lucilla; Aladowicz, Ewa; Fagiani, Ernesta; Lanfrancone, Luisa.

In: Expert Opinion on Therapeutic Targets, Vol. 13, No. 1, 01.2009, p. 93-104.

Research output: Contribution to journalArticle

Pasini, Luigi ; Turco, Margherita Y. ; Luzi, Lucilla ; Aladowicz, Ewa ; Fagiani, Ernesta ; Lanfrancone, Luisa. / Melanoma : Targeting signaling pathways and RaLP. In: Expert Opinion on Therapeutic Targets. 2009 ; Vol. 13, No. 1. pp. 93-104.
@article{27102ac427884839b1e7826f74c98617,
title = "Melanoma: Targeting signaling pathways and RaLP",
abstract = "Background: Metastatic melanoma remains one of the most aggressive forms of cancer, with a survival expectation of above six months only in rare cases. Despite advances in the characterization of the underlying molecular pathways and in the development of specific targeted treatments, available chemo- and immuno-therapy are unable to prolong survival significantly in advanced-stage melanoma. Rai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target. Objective: To summarize progress in the ongoing therapeutic approaches to metastatic melanoma and discuss RaLP as a potential novel therapeutic target. Methods: Current understanding of the major signaling pathways involved in melanoma metastatization and of the corresponding pharmacological inhibitors is discussed. Conclusion : RaLP might represent a new drugable target for the treatment of metastatic disease.",
keywords = "Metastatic melanoma, RaLP, Shc family, Targeted inhibitors",
author = "Luigi Pasini and Turco, {Margherita Y.} and Lucilla Luzi and Ewa Aladowicz and Ernesta Fagiani and Luisa Lanfrancone",
year = "2009",
month = "1",
doi = "10.1517/14728220802607363",
language = "English",
volume = "13",
pages = "93--104",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Melanoma

T2 - Targeting signaling pathways and RaLP

AU - Pasini, Luigi

AU - Turco, Margherita Y.

AU - Luzi, Lucilla

AU - Aladowicz, Ewa

AU - Fagiani, Ernesta

AU - Lanfrancone, Luisa

PY - 2009/1

Y1 - 2009/1

N2 - Background: Metastatic melanoma remains one of the most aggressive forms of cancer, with a survival expectation of above six months only in rare cases. Despite advances in the characterization of the underlying molecular pathways and in the development of specific targeted treatments, available chemo- and immuno-therapy are unable to prolong survival significantly in advanced-stage melanoma. Rai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target. Objective: To summarize progress in the ongoing therapeutic approaches to metastatic melanoma and discuss RaLP as a potential novel therapeutic target. Methods: Current understanding of the major signaling pathways involved in melanoma metastatization and of the corresponding pharmacological inhibitors is discussed. Conclusion : RaLP might represent a new drugable target for the treatment of metastatic disease.

AB - Background: Metastatic melanoma remains one of the most aggressive forms of cancer, with a survival expectation of above six months only in rare cases. Despite advances in the characterization of the underlying molecular pathways and in the development of specific targeted treatments, available chemo- and immuno-therapy are unable to prolong survival significantly in advanced-stage melanoma. Rai like protein (RaLP) is a newly identified Src homology 2 domain containing (Shc) family member selectively expressed during the transition to metastatic melanoma and thus is a potential melanoma-specific drugable target. Objective: To summarize progress in the ongoing therapeutic approaches to metastatic melanoma and discuss RaLP as a potential novel therapeutic target. Methods: Current understanding of the major signaling pathways involved in melanoma metastatization and of the corresponding pharmacological inhibitors is discussed. Conclusion : RaLP might represent a new drugable target for the treatment of metastatic disease.

KW - Metastatic melanoma

KW - RaLP

KW - Shc family

KW - Targeted inhibitors

UR - http://www.scopus.com/inward/record.url?scp=61449562203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449562203&partnerID=8YFLogxK

U2 - 10.1517/14728220802607363

DO - 10.1517/14728220802607363

M3 - Article

C2 - 19063709

AN - SCOPUS:61449562203

VL - 13

SP - 93

EP - 104

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -